臨床化学・免疫診断市場：製品タイプ別、エンドユーザー別-2025-2030年の世界予測

臨床化学・免疫診断市場は、2023年に376億7,000万米ドルと評価され、2024年には400億1,000万米ドルに達すると予測され、CAGR 6.41％で成長し、2030年には582億米ドルに達すると予測されています。

臨床化学・免疫診断市場には、診断や健康モニタリングの目的で体液を分析することに重点を置いた医療検査手順が含まれます。この分野は、慢性疾患の蔓延、人口の高齢化、個別化医療の出現により不可欠なものとなっています。アプリケーションは疾病診断、医薬品開発、患者モニタリングに及び、病院、診断ラボ、研究機関、ポイントオブケア検査施設など多様なエンドユーザーにサービスを提供しています。バイオマーカー探索の進歩、検査室の自動化、診断学における人工知能の統合が成長の原動力となっています。注目すべきビジネスチャンスは、遠隔地や資源の乏しい環境でのアクセシビリティを高めるための、費用対効果の高い迅速なPOC検査ソリューションの開発にあります。ゲノミクス、プロテオミクス、メタボロミクスを活用した個別化診断も、正確なヘルスケアソリューションを提供し、市場の視野を広げています。市場拡大を阻む課題としては、規制上の障害、研究開発コストの高さ、医療機器償還の複雑さなどが挙げられます。データのプライバシーに関する懸念や、高度な診断技術を管理する熟練した専門家の必要性が、さらに複雑さを増しています。こうした課題にもかかわらず、データ解析のための機械学習アルゴリズムの革新、診断機器の小型化、検査の感度と特異度の向上が大きな成長の道を示しています。この市場のダイナミックな性質は、急速な技術進歩や規制の適応によって大きく形成されており、企業の戦略策定には俊敏性が求められます。研究のための学術機関との協力関係を育み、官民パートナーシップに関与することは、スキルギャップを埋めるための強固なトレーニングプログラムへの投資と並んで、成長を促進する可能性があります。市場競争は激しいため、企業はM&Aによる地位の強化、製品ポートフォリオの拡大、顧客からのフィードバックを活用した技術革新に注力すべきです。未開拓の市場を継続的に開拓し、世界中のさまざまな経済セグメントに対応するソリューションを適応させることは、成長を維持し、この進化する市場情勢で競争力を獲得する上で極めて重要です。

市場力学：急速に進化する臨床化学・免疫診断市場の主要市場インサイトを公開

臨床化学・免疫診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加と慢性疾患の流行
  • 臨床化学・免疫診断技術の採用に対する政府の積極的な取り組み
  • ポイントオブケア検査の重要性と認知度の高まり
• 市場抑制要因
  • 化学・免疫診断製品のリコール問題
• 市場機会
  • 臨床化学および免疫診断機器における継続的な技術進歩
  • 遠隔医療と個別化治療における臨床化学・免疫診断の可能性の高まり
• 市場の課題
  • 製品開発および商業化における規制基準の厳しさと多様性

ポーターのファイブフォース：臨床化学・免疫診断市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：臨床化学・免疫診断市場における外部からの影響の把握

外部マクロ環境要因は、臨床化学・免疫診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析臨床化学・免疫診断市場における競合情勢の把握

臨床化学・免疫診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス臨床化学・免疫診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、臨床化学・免疫診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨臨床化学・免疫診断市場における成功への道筋を描く

臨床化学・免疫診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と慢性疾患の増加
    • 臨床化学・免疫診断技術の導入に対する政府の好意的な取り組み
    • ポイントオブケア検査の重要性と認識の高まり
  • 抑制要因
    • 化学および免疫診断製品のリコールに関連する問題
  • 機会
    • 臨床化学および免疫診断機器における継続的な技術進歩
    • 遠隔医療と個別化治療における臨床化学・免疫診断の潜在的可能性の拡大
  • 課題
    • 製品開発と商品化に関する厳格で多様な規制基準
• 市場セグメンテーション分析
  • 製品タイプ：既存の病院情報システムと簡単に統合できるモジュール式で拡張可能なシステムの採用
  • エンドユーザー：機器における高度な技術統合への注目が高まる
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 臨床化学・免疫診断市場：製品タイプ別

• 機器
• 試薬

第7章 臨床化学・免疫診断市場：エンドユーザー別

• 診断検査室
• 病院

第8章 南北アメリカの臨床化学・免疫診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の臨床化学・免疫診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの臨床化学・免疫診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ベックマン・コールターのDxC 500 AU化学分析装置のイントロダクション
  • 富士レビオホールディングスとアガッペ・ダイアグノスティクスがインドにおける化学発光免疫測定法の生産に革命を起こす戦略的提携
  • ロシュ、LumiraDx Point of Careテクノロジーの買収により診断ポートフォリオを拡大
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Accurex Biomedical Private Limited
• Agappe Diagnostics Ltd.
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Cardinal Health, Inc.
• Chengdu Seamaty Technology Co., Ltd.
• Danaher Corporation
• DiaSorin S.p.A
• ELITechGroup by Bruker Corporation
• F. Hoffmann-La Roche Ltd.
• GenviewDX
• H.U. Group Holdings Inc.
• Hitachi, Ltd.
• HORIBA, Ltd.
• Immuno Diagnostics Pvt. Ltd.
• Medix Biochemica AB
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• QuidelOrtho Corporation
• Sekisui Medical Co. Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc.
• viSole The Solution

LIST OF FIGURES

• FIGURE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 2. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 21. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 100. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

The Clinical Chemistry & Immunodiagnostic Market was valued at USD 37.67 billion in 2023, expected to reach USD 40.01 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 58.20 billion by 2030.

The Clinical Chemistry & Immunodiagnostic market involves medical testing procedures that focus on analyzing bodily fluids for diagnostic and health monitoring purposes. This sector is integral due to chronic disease prevalence, aging populations, and the advent of personalized medicine. Applications span disease diagnosis, drug development, and patient monitoring, serving diverse end-users such as hospitals, diagnostic labs, research institutions, and point-of-care testing facilities. Growth is fueled by advancements in biomarker discovery, automation in laboratories, and the integration of artificial intelligence in diagnostics. A notable opportunity lies in developing cost-effective, rapid point-of-care testing solutions to enhance accessibility in remote or resource-poor settings. Personalized diagnostics, which leverage genomics, proteomics, and metabolomics, are also expanding the market's horizon, offering precise healthcare solutions. Challenges hindering market expansion include regulatory obstacles, high RD costs, and complexities in medical device reimbursement. Data privacy concerns and the need for skilled professionals to manage sophisticated diagnostic technologies add further layers of complexity. Despite these challenges, innovation in machine learning algorithms for data analysis, miniaturization of diagnostic devices, and enhancing the sensitivity and specificity of tests present significant growth avenues. The dynamic nature of this market is largely shaped by rapid technological progress and regulatory adaptations, demanding agility in strategy formulation for companies. Fostering collaborations with academic institutions for research and engaging in public-private partnerships could catalyze growth, alongside investing in robust training programs to bridge skill gaps. As the market is highly competitive, businesses should focus on consolidating their positions through mergers and acquisitions, expanding their product portfolios, and leveraging customer feedback to innovate. Continuous exploration of untapped markets and the adaptation of solutions to cater to varied economic segments worldwide will be crucial in sustaining growth and gaining a competitive edge in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Chemistry & Immunodiagnostic Market

The Clinical Chemistry & Immunodiagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising elderly population and growing prevalence of chronic diseases
  • Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
  • Growing importance and awareness of point-of-care testing
• Market Restraints
  • Issues associated with chemistry and immunodiagnostic product recall
• Market Opportunities
  • Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
  • Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
• Market Challenges
  • Stringent and varying regulatory standards for product development and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Chemistry & Immunodiagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Chemistry & Immunodiagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Chemistry & Immunodiagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Chemistry & Immunodiagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Chemistry & Immunodiagnostic Market

A detailed market share analysis in the Clinical Chemistry & Immunodiagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Chemistry & Immunodiagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Chemistry & Immunodiagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Chemistry & Immunodiagnostic Market

A strategic analysis of the Clinical Chemistry & Immunodiagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Chemistry & Immunodiagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accurex Biomedical Private Limited, Agappe Diagnostics Ltd., Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Inc., Chengdu Seamaty Technology Co., Ltd., Danaher Corporation, DiaSorin S.p.A, ELITechGroup by Bruker Corporation, F. Hoffmann-La Roche Ltd., GenviewDX, H.U. Group Holdings Inc., Hitachi, Ltd., HORIBA, Ltd., Immuno Diagnostics Pvt. Ltd., Medix Biochemica AB, QIAGEN N.V., Quest Diagnostics Incorporated, QuidelOrtho Corporation, Sekisui Medical Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens AG, Thermo Fisher Scientific Inc., and viSole The Solution.

Market Segmentation & Coverage

This research report categorizes the Clinical Chemistry & Immunodiagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Instruments and Reagents.
• Based on End-user, market is studied across Diagnostic Laboratories and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising elderly population and growing prevalence of chronic diseases
    • 5.1.1.2. Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
    • 5.1.1.3. Growing importance and awareness of point-of-care testing
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with chemistry and immunodiagnostic product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
    • 5.1.3.2. Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent and varying regulatory standards for product development and commercialization
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Adoption of modular and scalable systems that easily integrate with existing hospital information systems
  • 5.2.2. End-user: Growing focus on advanced technological integration in instruments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Clinical Chemistry & Immunodiagnostic Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents

7. Clinical Chemistry & Immunodiagnostic Market, by End-user

• 7.1. Introduction
• 7.2. Diagnostic Laboratories
• 7.3. Hospitals

8. Americas Clinical Chemistry & Immunodiagnostic Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Clinical Chemistry & Immunodiagnostic Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Clinical Chemistry & Immunodiagnostic Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Introduction of Beckman Coulter's DxC 500 AU Chemistry Analyzer
  • 11.3.2. Strategic Partnership Between Fujirebio Holdings and Agappe Diagnostics to Revolutionize Chemiluminescence Immunoassay Production in India
  • 11.3.3. Roche Expands Diagnostics Portfolio with Acquisition of LumiraDx Point of Care Technology
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accurex Biomedical Private Limited
• 3. Agappe Diagnostics Ltd.
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Cardinal Health, Inc.
• 7. Chengdu Seamaty Technology Co., Ltd.
• 8. Danaher Corporation
• 9. DiaSorin S.p.A
• 10. ELITechGroup by Bruker Corporation
• 11. F. Hoffmann-La Roche Ltd.
• 12. GenviewDX
• 13. H.U. Group Holdings Inc.
• 14. Hitachi, Ltd.
• 15. HORIBA, Ltd.
• 16. Immuno Diagnostics Pvt. Ltd.
• 17. Medix Biochemica AB
• 18. QIAGEN N.V.
• 19. Quest Diagnostics Incorporated
• 20. QuidelOrtho Corporation
• 21. Sekisui Medical Co. Ltd.
• 22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 23. Siemens AG
• 24. Thermo Fisher Scientific Inc.
• 25. viSole The Solution